419 related articles for article (PubMed ID: 37486518)
1. Genome Editing for Engineering the Next Generation of Advanced Immune Cell Therapies.
de Lima SCG; Fantacini DMC; Furtado IP; Rossetti R; Silveira RM; Covas DT; de Souza LEB
Adv Exp Med Biol; 2023; 1429():85-110. PubMed ID: 37486518
[TBL] [Abstract][Full Text] [Related]
2. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.
Dimitri A; Herbst F; Fraietta JA
Mol Cancer; 2022 Mar; 21(1):78. PubMed ID: 35303871
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy.
Gao Q; Dong X; Xu Q; Zhu L; Wang F; Hou Y; Chao CC
Cancer Med; 2019 Aug; 8(9):4254-4264. PubMed ID: 31199589
[TBL] [Abstract][Full Text] [Related]
4. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy.
Liu X; Zhao Y
Curr Res Transl Med; 2018 May; 66(2):39-42. PubMed ID: 29691200
[TBL] [Abstract][Full Text] [Related]
6. Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.
Rath JA; Arber C
Cells; 2020 Jun; 9(6):. PubMed ID: 32570906
[TBL] [Abstract][Full Text] [Related]
7. Paving New Roads for CARs.
Hyrenius-Wittsten A; Roybal KT
Trends Cancer; 2019 Oct; 5(10):583-592. PubMed ID: 31706506
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy.
Salas-Mckee J; Kong W; Gladney WL; Jadlowsky JK; Plesa G; Davis MM; Fraietta JA
Hum Vaccin Immunother; 2019; 15(5):1126-1132. PubMed ID: 30735463
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy.
Huang D; Miller M; Ashok B; Jain S; Peppas NA
Adv Drug Deliv Rev; 2020; 158():17-35. PubMed ID: 32707148
[TBL] [Abstract][Full Text] [Related]
11. Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing.
Liu J; Zhou G; Zhang L; Zhao Q
Front Immunol; 2019; 10():456. PubMed ID: 30941126
[TBL] [Abstract][Full Text] [Related]
12. Genetical engineering for NK and T cell immunotherapy with CRISPR/Cas9 technology: Implications and challenges.
Zhi L; Su X; Yin M; Zhang Z; Lu H; Niu Z; Guo C; Zhu W; Zhang X
Cell Immunol; 2021 Nov; 369():104436. PubMed ID: 34500148
[TBL] [Abstract][Full Text] [Related]
13. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells.
MacLeod DT; Antony J; Martin AJ; Moser RJ; Hekele A; Wetzel KJ; Brown AE; Triggiano MA; Hux JA; Pham CD; Bartsevich VV; Turner CA; Lape J; Kirkland S; Beard CW; Smith J; Hirsch ML; Nicholson MG; Jantz D; McCreedy B
Mol Ther; 2017 Apr; 25(4):949-961. PubMed ID: 28237835
[TBL] [Abstract][Full Text] [Related]
14. CAR T cells: Building on the CD19 paradigm.
Globerson Levin A; Rivière I; Eshhar Z; Sadelain M
Eur J Immunol; 2021 Sep; 51(9):2151-2163. PubMed ID: 34196410
[TBL] [Abstract][Full Text] [Related]
15. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells.
Hiltensperger M; Krackhardt AM
Front Immunol; 2023; 14():1121030. PubMed ID: 36949949
[TBL] [Abstract][Full Text] [Related]
16. Strategies to Enhance the Therapeutic Efficacy, Applicability, and Safety of Genetically Engineered Immune Cells.
de Lima SCG; Fantacini DMC; Batista LC; Silveira RM; Furtado IP; Rossetti R; Brand H; Covas DT; de Souza LEB
Crit Rev Immunol; 2021; 41(1):41-67. PubMed ID: 33822524
[TBL] [Abstract][Full Text] [Related]
17. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
Shum T; Kruse RL; Rooney CM
Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
[TBL] [Abstract][Full Text] [Related]
18. Genome-edited allogeneic donor "universal" chimeric antigen receptor T cells.
Qasim W
Blood; 2023 Feb; 141(8):835-845. PubMed ID: 36223560
[TBL] [Abstract][Full Text] [Related]
19. Elucidation of CRISPR-Cas9 application in novel cellular immunotherapy.
Quazi S
Mol Biol Rep; 2022 Jul; 49(7):7069-7077. PubMed ID: 35122203
[TBL] [Abstract][Full Text] [Related]
20. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
